Table 3.
Main results of COVID-19 and dengue coinfection studies included.
| Authors | Year | Design | Country | Cases (N) | Age (Years) Median (IQR) |
Sex N (%) |
Diagnosis method |
Serotype of dengue N (%) |
Hospitalization (days) Median (IQR) |
Outcome N (%) |
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| COVID-19 N (%) |
Dengue N (%) |
||||||||||
| Carosella L et al. [37] | 2021 | Retrospective analysis | Argentina | 13 | 37 (29-50) | Male: 7 (54.0) Female: 6 (46.0) |
Real time-PCR SARS-CoV-2 +: 13 (100.0) | NS1 DENV +: 8 (61.5) RT - PCR +: 4 (30.8) Seroconvertion: 1 (7.7) |
NR | 12.0 (10.0 - 14.0) | Death: 0 (0.0) Discharged: 13 (100.0) |
| Mejía J et al. [38] | 2021 | Retrospective analysis | Peru | 50 | 55.5 (40.5 - 65) | Male: 39 (78.0) Female: 11 (22) |
SARS-CoV-2 IgG/IgM +: 39 (78.0) Real time-PCR SARS-CoV-2+: 4 (8.0) SARS-CoV-2 IgM +: 4 (8.0) SARS-CoV-2 IgG +: 3 (6.0) |
NS1 DENV + †: 30 (60.0) DENV IgM + ‡: 19 (38.0) DENV IgM/IgG + b: 1 (2.0) |
NR | NR | Dead: 14 (28.0) Discharged: 36 (72.0) |
| Soares I et al. [39] | 2021 | Retrospective cohort | Brazil | 43 | NR | NR | RT-PCR SARS-CoV-2 +: 43 (100.0) SARS-CoV-2 IgM + : 43(100.0) |
DENV IgM+: 43 (100.0) | NR | NR | NR |
| StringariI L et al. [40] | 2021 | Retrospective cohort | Brazil | 2 | 55.5 ± 6.36 | Females: 2 (100.0) | SARS-CoV-2 IgG +: 2 (100.0) | DENV IgM and IgG: 2 (100.0) | NR | NR | NR |
| Rosso et al. [30] | 2021 | Cross-sectional | Colombia | 2 | NR | NR | RT-PCR SARS-CoV-2+: 2 (100.0) | RT-PCR +: 1 (50.0) Seroconvertion +: 1 (50.0) | DENV 1-4: 1 (50.0) | NR | NR |
| Schulte H et al. [35] | 2021 | Retrospective cohort | Brazil | 13 | 27 - 79 | Male: 6 (46.2) Female: 7 (53.8) |
RT-PCR SARS-CoV-2 +: 13 (100.0) | NS1 DENV +: 6 (46.2) DENV IgM +: 7 (53.8)" |
NR | 12.0 (10.0 - 14.0) | Clinical improvement: 13 (100.0) Death: 0 (0.0) |
†Patients with less than five days of symptoms.
‡Patients with symptoms more significant than five days.
+Positive. DENV 1-4: dengue virus serotype 1 and 4; NS1: nonstructural protein 1; Real time-PCR: real-time polymerase chain reaction; RT-PCR: reverse transcription-polymerase chain reaction; Seroconvertion: persistence of positive anti-DENV antibodies 24 days after onset of symptoms.